Abstract:Objective ：This study aims to analyze the clinical features, prognostic characteristics and gene mutations of the primary myelodysplastic syndrome with myelofibrosis (MDS-MF) patients, ultimately to improve the cognition of MDS-MF. Methods ：From January 1, 2013 to February 1, 2020, 417 newly diagnosed primary MDS patients in the first affiliated hospital of Zhejiang University with bone marrow (BM) biopsy examination were included. They were divided into two groups according to whether BM associated with fibrosis (2005 European Myelofibrosis Network criteria), the MDS-MF group(MF grades 1-3）and the MDS without MF group (MDS-MF0).The clinical features, prognosis characteristics and gene alterations were analyzed between the two groups retrospectively. Results ： ① MF was confirmed in 46.3％（193/417）cases of all the MDS patients, of which 66.3％（128/193）were MF-1 , 25.9％（50/193）were MF-2 and 7.8%(15/193) were MF-3 respectively. The proportion of MDS-EB in MDS-MF group was 48.2%(93/193) and significantly higher than in MDS-MF0 group 35.7%（80/224）,the difference had statistical significance(P=0.008). However, the occurrence of MF does not differ among the MDS subtypes according to the 2016 WHO classification (P=0.342). ② The clinical features of the two groups had statistically significant differences in the higher number of BM blast cells(P=0.006), higher prevalence of death (P=0.031), higher rate of Leukemic transformation (P<0.001), higher level of serum lactate dehydrogenase (LDH) in the peripheral blood (p<0.001), higher level of β2-microgram in the peripheral blood(p=0.003) and higher level of C-reactive Protein (CRP) in the peripheral blood (P=0.004) in the MDS-MF group than in the MDS-MF0 group. The number of WBC, Hb, PLT and Ferritin at the first diagnosed in our hospital were no difference compared the two groups (All P>0.05). The sex, Age and the IPSS-R score(IPSS-R >3.5 v ≤3.5) were no difference in the two groups (ALL P>0.05). ③Compared with MDS-MF0 group, MDS-MF were significantly associated with worse OS(P=0.035) and worse PFS(p<0.001). The median overall survival was 13.20(0.07-90.70) months in MDS-MF group, and was 23.77(0.53-98.97) months in MDS-MF0 group respectively. Subgroup analysis showed that both OS and PFS of either the MDS-MF1-2 group or the MDS-MF 3 group were also significantly worse than those of the MDS-MF0 group（P＝0.013 and <0.001 respectively）. ④Among all the patients ,337 were finished Next-generation-sequencing (NGS) test, sequencing errors and all known or possible single-nucleotide polymorphisms were excluded. The number of mutations (>2) was more frequently in the MDS-MF, the difference had statical significance(P=0.030). The RNA splicing was more frequently in the MDS-MF than the MDS without MF, the difference also had statical difference(P=0.025). The ratio of U2AF1 mutation occurred in MDS-MF group higher than MDS-MF0 group, the difference had statical significance (P=0.027). There was totally 14.2% (48/337) patients with the mutation of U2AF1, of which 19.7%（29/147) in MDS-MF group and 10.0%（19/190) in MDS-MF0 group. Conclusion: MDS-MF has unique laboratory and clinical characteristics. MF is an independent risk factor for shorter overall survival (OS) and worse progression-free survival (PFS) in primary MDS. Evaluation of MF is very significant for prognosis judgment in primary MDS. The U2AF1 mutation may be a biomarker related to the occurrence and poor prognosis of MDS-MF. However, the mechanism of U2AF1 in MDS-MF patient needs to be further explored. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Clinical Assessment of FAB and WHO Classification of Myelodysplastic Syndromes

Clinical and Biological Characteristics of Acute Myeloid Leukemia with 20-29% Blasts: a Retrospective Single-Center Study

MICM Classifications Analysis of Adult Acute Lymphoblastic Leukemia

Analysis of the Karyotype Abnormalities and Its Prognostic in 298 Patients with Myelodysplastic Syndrome

A comparative study of MDS-RAEB,MDS-RAEBT and AML in the elderly

Cytogenetic Abnormalities Predict Disease Progression in Primary Myelodysplastic Syndrome: A Multicentric Study in 508 Chinese Patients.

Clinical Characterization and Prognostic Factors of 144 Adult Acute Monocytic Leukemia

Analysis of Clinical Features, Prognostic Characteristics and Gene Mutations of Primary Myelodysplastic Syndrome Patients with Myelofibrosis

Real-World Analysis of Clinical Outcomes in AML, Myelodysplasia-Related: a Comparison of ICC and WHO-HAEM5 Criteria

[Prospective Clinical Study of Diagnosis and Classification for 282 Cases with Primary Myelodysplastic Syndrome].

Clinical analysis for thirty patients with myelodysplastic syndromes

Re-evaluation of refractory anemia with excess blasts in transformation

Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms

The classification of MDS: from FAB to WHO and beyond

Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT

Prognostic Analysis of Refractory Anaemia in Adult Myelodysplastic Syndromes.

Value Of Flow Cytometry For Differential Diagnosis Between Refractory Cytopenia With Multilineage Dysplasia And Aplastic Anemia

Advances towards genome‐based acute myeloid leukemia classification: A comparative analysis of WHO‐HAEM4R, WHO‐HAEM5, and International Consensus Classification

The ratio of bone marrow myeloid progenitor cell proportion to mature lymphocytes proportion can effectively differentiate aplastic anemia and hypoplastic myelodysplastic syndrome and evaluate the quality of bone marrow aspirates

[The Value of Flow Cytometry for the Differential Diagnosis Between Refractory Cytopenia with Multiple Dysplasia and Aplastic Anemia].

Prospective Analysis of Clinical and Cytogenetic Features of 435 Cases of Mds Diagnosed Using the Who (2001) Classification: A Prognostic Scoring System for Predicting Survival in Rcmd